Hypertrophic scars (HSs) can cause significant aesthetic and functional symptoms and
to-date no optimal treatment has been established. Many causes have been associated
with HS development but regardless, it presents with appearance of myofibroblasts
and an abnormal deposition of extracellular matrix (ECM) collagens. This accumulation
makes ECM a logical target for pharmacological interventions, and researchers are
endeavouring to modify ECM metabolism.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Plastic, Reconstructive & Aesthetic SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- TGF-beta: a fibrotic factor in wound scarring and a potential target for anti-scarring gene therapy.Curr Gene Ther. 2004; 4: 123-136
- Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars.Acta Derm Venereol. 2005; 85: 216-220
- Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-β receptor II.J Plast Reconstr Aesth Surg. 2006; 59: 64-72
- Inhibiting scar formation in rat wounds by adenovirus-mediated overexpression of truncated TGF-beta receptor II.Plast Reconstr Surg. 2005; 115: 860-870
- Remote delivery and expression of soluble type II TGF-beta receptor in muscle prevents hepatic fibrosis in rats.Int J Mol Med. 2005; 16: 59-64
- Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.Cancer Res. 2005; 65: 2296-2302
- Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-β receptor exhibit impaired mammary development and enhanced mammary tumor formation.Am J Pathol. 2003; 163: 1539-1549
Article info
Publication history
Published online: May 04, 2006
Identification
Copyright
© 2006 The British Association of Plastic Surgeons. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-β receptor IIJournal of Plastic, Reconstructive & Aesthetic SurgeryVol. 60Issue 1
- PreviewEffective blockade of the pluripotent cytokine transforming growth factor (TGF)-β as a means of cutaneous scar reduction is a strategy with great potential. This desired effect may be achieved through the overexpression of mutant TGF-β receptors within the wound milieu. Our goal was to examine the effects of dominant negative mutant TGF-β receptor II (TGFβRIIdn) protein expression in a well-established rabbit ear model of hypertrophic scarring. Serial injections of a retroviral construct encoding a truncated TGFβRII and the marker green fusion protein (pMSCV-rIIdn-GFP) were performed in 7 mm punch wounds at day 10 and day 12 (two-day injection group) or days 8, 10, 12 (three-day injection group) post-wounding.
- Full-Text
- Preview
